Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label long-term safety study of daily oral BCX7353 in hereditary angioedema
2017-003281-27Phase 2Unknown
- Sponsor
- BioCryst Pharmaceuticals, Inc.
- Start
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of berotralstat in hereditary angioedema type I (HAE-I) and Hereditary Angioedema Type 2 (HAE2) (2 arms), sponsored by BioCryst Pharmaceuticals, Inc. Primary endpoint: Discontinuation due to treatment-emergent adverse events. Status: unknown.
02
Drugs
berotralstat
03
Conditions
hereditary angioedema type I (HAE-I)Hereditary Angioedema Type 2 (HAE2)
Beyond the preview
Go deeper on 2017-003281-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003281-27.